Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pulmonx (LUNG) Operating Expenses (2019 - 2025)

Pulmonx has reported Operating Expenses over the past 7 years, most recently at $30.4 million for Q3 2025.

  • Quarterly Operating Expenses rose 4.42% to $30.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $93.4 million through Dec 2025, down 22.01% year-over-year, with the annual reading at $119.7 million for FY2024, 6.23% up from the prior year.
  • Operating Expenses was $30.4 million for Q3 2025 at Pulmonx, down from $32.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $32.0 million in Q2 2025 and troughed at $19.1 million in Q1 2021.
  • The 5-year median for Operating Expenses is $28.2 million (2023), against an average of $26.7 million.
  • Year-over-year, Operating Expenses soared 73.16% in 2021 and then rose 3.37% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $22.6 million in 2021, then rose by 14.12% to $25.8 million in 2022, then rose by 9.72% to $28.3 million in 2023, then grew by 9.49% to $31.0 million in 2024, then decreased by 1.81% to $30.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Operating Expenses are $30.4 million (Q3 2025), $32.0 million (Q2 2025), and $30.9 million (Q1 2025).